The polyphenol (−)-epigallocatechin-3-gallate prevents apoA-I_Iowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity

References

• Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50:S189–94
   PubMed Web of Science ®Google Scholar
• Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999;100:1816–22
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 1996;7:82–7
   PubMed Web of Science ®Google Scholar
• Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992;33:141–66
   PubMed Web of Science ®Google Scholar
• Mei X, Atkinson D. Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J Biol Chem 2011;286:38570–82
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75:333–66
   PubMed Web of Science ®Google Scholar
• Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, Lohse P, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 2009;11:257–62
   PubMed Web of Science ®Google Scholar
• Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 2002;12:121–8
   PubMed Web of Science ®Google Scholar
• Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G, Bellotti V. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 2006;13:191–205
   PubMed Web of Science ®Google Scholar
• Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 2011;179:1978–87
   PubMed Web of Science ®Google Scholar
• Van Allen MW, Frohlich JA, Davis JR. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy and peptic ulcer. Neurology 1969;19:10–25
   PubMed Web of Science ®Google Scholar
• Nichols WC, Gregg RE, Brewer Jr HB, Benson MD. A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990;8:318–23
   PubMed Web of Science ®Google Scholar
• Adachi E, Nakajima H, Mizuguchi C, Dhanasekaran P, Kawashima H, Nagao K, Akaji K, et al. Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. J Biol Chem 2013;288:2848–56
   PubMed Web of Science ®Google Scholar
• Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006;443:774–9
   PubMed Web of Science ®Google Scholar
• Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006;67:27–37
   PubMed Web of Science ®Google Scholar
• Higdon JV, Frei B. Tea catechins and polyphenols, health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003;43:89–143
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15:558–66
   PubMed Web of Science ®Google Scholar
• Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 2010;107:7710–15
   PubMed Web of Science ®Google Scholar
• Meng F, Abedini A, Plesner A, Verchere CB, Raleigh DP. The flavanol (–)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 2010;49:8127–33
   PubMed Web of Science ®Google Scholar
• Bae SY, Kim S, Hwang H, Kim HK, Yoon HC, Kim JH, Lee S, et al. Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR). Biochem Biophys Res Commun 2010;400:531–6
   PubMed Web of Science ®Google Scholar
• Kamihira-Ishijima M, Nakazawa H, Kira A, Naito A, Nakayama T. Inhibitory mechanism of pancreatic amyloid fibril formation: formation of the complex between tea catechins and the fragment of residues 22-27. Biochemistry 2012;51:10167–74
   PubMed Web of Science ®Google Scholar
• Engel MF, vandenAkker CC, Schleeger M, Velikov KP, Koenderink GH, Bonn M. The polyphenol EGCG inhibits amyloid formation less efficiently at phospholipid interfaces than in bulk solution. J Am Chem Soc 2012;134:14781–8
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008;1214:177–87
   PubMed Web of Science ®Google Scholar
• Bastianetto S, Yao ZX, Papadopoulos V, Quirion R. Neuroprotective effects of green and black teas and their catechin gallate esters against β-amyloid-induced toxicity. Eur J Neurosci 2006;23:55–64
   PubMed Web of Science ®Google Scholar
• Nonaka G, Kawahara O, Nishioka I. Tannins and related compounds. XV. A new class of dimeric flavan-3-ol gallates, theasinensins A and B, and proanthocyanidin gallates from green tea leaf. (1). Chem Pharm Bull 1983;31:3906–14
   Web of Science ®Google Scholar
• Kuwabara K, Nishitsuji K, Uchimura K, Hung SC, Mizuguchi M, Nakajima H, Mikawa S, et al. Cellular interaction and cytotoxicity of the Iowa mutation of apolipoprotein A-I (apoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate. J Biol Chem 2015;290:24210–21
   PubMed Web of Science ®Google Scholar
• Tanaka M, Koyama M, Dhanasekaran P, Nguyen D, Nickel M, Lund-Katz S, Saito H, et al. Influence of tertiary structure domain properties on the functionality of apolipoprotein A-I. Biochemistry 2008;47:2172–80
   PubMed Web of Science ®Google Scholar
• Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 1989;177:244–9
   PubMed Web of Science ®Google Scholar
• Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001; 40:6036–46
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63
   PubMed Web of Science ®Google Scholar
• LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992;5:227–31
   PubMed Web of Science ®Google Scholar
• Paz MA, Fluckiger R, Boak A, Kagan HM, Gallop PM. Specific detection of quinoproteins by redox-cycling staining. J Biol Chem 1991;266:689–92
   PubMed Web of Science ®Google Scholar
• Harper JD, Lansbury Jr PT. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997;66:385–407
   PubMed Web of Science ®Google Scholar
• Cao P, Raleigh DP. Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. Biochemistry 2012;51:2670–83
   PubMed Web of Science ®Google Scholar
• Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, et al. Fibril specific: conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007;2:18
   PubMed Web of Science ®Google Scholar
• Pellarin R, Caflisch A. Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol 2006;360:882–92
   PubMed Web of Science ®Google Scholar
• Chandrashekaran IR, Adda CG, Macraild CA, Anders RF, Norton RS. EGCG disaggregates amyloid-like fibrils formed by Plasmodium falciparum merozoite surface protein 2. Arch Biochem Biophys 2011;513:153–7
   PubMed Web of Science ®Google Scholar
• Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J. The green tea polyphenol (−)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett 2015;589:77–83
   PubMed Web of Science ®Google Scholar
• Palhano FL, Lee J, Grimster NP, Kelly JW. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc 2013;135:7503–10
   PubMed Web of Science ®Google Scholar
• Ando Y, Suhr O, el-Salhy M. Oxidative stress and amyloidosis. Histol Histopathol 1998;13:845–50
   PubMed Web of Science ®Google Scholar
• Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997;387:561
   PubMed Web of Science ®Google Scholar
• Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A. Polyphenolic antioxidant (–)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. Aids 2002;16:939–41
   PubMed Web of Science ®Google Scholar
• Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (–)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1:2:3:6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001;78:1073–82
   PubMed Web of Science ®Google Scholar
• Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Bai G, Saraiva MJ, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 2009;583:3569–76
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Brender JR, Hartman K, Ramamoorthy A, Marsh ENG. Alternative pathways of human islet amyloid polypeptide aggregation distinguished by 19F nuclear magnetic resonance-detected kinetics of monomer consumption. Biochemistry 2012;51:8154–62
   PubMed Web of Science ®Google Scholar
• Castellano LM, Hammond RM, Holmes VM, Weissman D, Shorter J. Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils. Biol Open 2015;4:1206–12
   PubMed Web of Science ®Google Scholar
• Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R III, et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener 2010;5:57
   PubMed Web of Science ®Google Scholar
• Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B, et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005;102:10427–32
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 2004;279:31374–82
   PubMed Web of Science ®Google Scholar
• Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med 2014;6:1493–507
   PubMed Web of Science ®Google Scholar
• Gorbenko GP, Kinnunen PK. The role of lipid-protein interactions in amyloid-type protein fibril formation. Chem Phys Lipids 2006;141:72–82
   PubMed Web of Science ®Google Scholar
• Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, et al. Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 2008;27:224–33
   PubMed Web of Science ®Google Scholar